CCM® Overview - Provider Education

September 1, 2020

This animation provides an overview of CCM therapy including the indications for use, recommendations for patient selection, and a brief review of mechanism of action.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login